[1] Caicedo-Herrera G,Candelo E,Pinilla J,et al.Novel ATP7A gene mutation in a patient with Menkes disease[J].Appl Clin Genet,2018,11:151-155.
[2] Patel P,Prabhu AV,Benedek TG.The history of john hans Menkes and Kinky hair syndrome[J].JAMA Dermatol,2017,153(1):54.
[3] Rangarh P,Kohli N.Neuroimaging findings in Menkes disease:a rare neurodegenerative disorder[J].Bmj Case Reports,2018,2018:bcr-2017-223858.doi:10.1136/bcr-2017-223858
[4] 李杏,袁海,陈晓兰,等.Menkes病一家系的临床与遗传学研究[J].中华实用儿科临床杂志,2018,33(24):1900-1902.
[5] Skjørringe T,Amstrup PP,Salling TS,et al.Characterization of ATP7A missense mutants suggests a correlation between intracellular trafficking and severity of Menkes disease[J].Sci Rep,2017,7:757.
[6] Prithvi A,Sharawat IK,Saini AG,et al.Epilepsy and neurodegeneration:Clues in the hair and blood vessels![J].J Pediatr,2019,206:293-293.
[7] Bonati MT,Verde F,Hladnik U,et al.A novel nonsense ATP7A pathogenic variant in a family exhibiting a variable occipital horn syndrome phenotype[J].Mol Genet Metab Rep,2017,13:14-17.
[8] Verrotti A,Cusmai R,Darra F,et al.Epilepsy in Menkes disease:an electroclinical long-term study of 28 patients[J].Epilepsy Res,2014,108(9):1597-1603.
[9] Altarelli M,Ben-Hamouda N,Schneider A,et al.Copper deficiency:causes,manifestations,and treatment[J].Nutr Clin Pract,2019.doi:10.1002/ncp.10328.
[10] Vairo FPE,Chwal BC,Perini S,et al.A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease[J].Mol Genet Metab,2019,126(1):6-13.
[11] Giampietro R,Spinelli F,Contino M,et al.The pivotal role of copper in neurodegeneration:a new strategy for the therapy of neurodegenerative disorders[J].Mol Pharm,2018,15(3):808-820.
[12] Tumer Z,Petris M,Zhu S,et al.A 37-year-old Menkes disease patient-residual ATP7A activity and early copper administration as key factors in beneficial treatment[J].Clin Genet,2017,92(5):548-553.
[13] Bhattacharjee A,Yang H,Duffy M,et al.The activity of Menkes disease protein ATP7A is essential for redox balance in mitochondria[J].J Biol Chem,2016,291(32):16644-16658.
[14] Yoganathan S,Sudhakar SV,Arunachal G,et al.Menkes disease and response to copper histidine:an Indian case series[J].Ann Indian Acad Neurol,2017,20(1):62-68.
[15] Horn N,Moller LB,Nurchi VM,et al.chelating principles in Menkes and Wilson diseases:choosing the right compounds in the right combinations at the right time[J].J Inorg Biochem,2019,190:98-112.
[16] Rakshit A,Khatua K,Shanbhag V,et al.Cu²⁺ selective chelators relieve copper-induced oxidative stress in vivo[J].Chem Sci,2018,9(41):7916-7930.
[17] Munakata M,Kodama H,Tani N,et al.Menkes disease:oral administration of glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) rescues the macular mouse[J].Pediatr Res,2018.doi:10.1038/s41390-018-0116-7.
[18] Hoshina T,Nozaki S,Hamazaki T,et al.Disulfiram enha nced delivery of orally administered copper into the central nervous system in Menkes disease mouse model[J].J Inherit Metab Dis,2018,41(6):1285-1291.
[19] Ogata R,Chong PF,Maeda K,et al.Long surviving classical Menkes disease treated with weekly intravenous copper therapy[J].J Trace Elem Med Biol,2019,54:172-174.
[20] Lem KE,Brinster LR,Tjurmina O,et al.Safety of intracerebroventricular copper histidine in adult rats[J].Molecular Genetics & Metabolism,2007,91(1):30-36.
[21] Fieten H,Gill Y,Martin AJ,et al.The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador retrievers:a new canine model for copper-metabolism disorders[J].Dis Model Mech,2016,9(1):25-38.
[22] Lichtmannegger J,Leitzinger C,Wimmer R,et al.Methanobactin reverses acute liver failure in a rat model of Wilson disease[J].J Clin Invest,2016,126(7):2721-2735.
[23] Chong DJ,Lerman AM.Practice update:review of anticonvulsant therapy[J].Curr Neurol Neurosci Rep,2016,16(4):39.
[24] Go CY,Mackay MT,Weiss SK,et al.Evidence-based guideline update:medical treatment of infantile spasms.Report of the guideline development subcommittee of the American academy of neurology and the practice committee of the child neurology society[J].Neurology,2012,78(24):1974-1980.
[25] Ismayilova N,Leung MA,Kumar R,et al.Ketogenic diet therapy in infants less than two years of age for medically refractory epilepsy[J].Seizure,2018,57:5-7.
[26] Ojha R,Prasad AN.Menkes disease:what a multidisciplinary approach can do[J].J Multidiscip Healthc,2016,9:371-385.
[27] Salar S,Moshé SL,Galanopoulou AS.Metabolic etiologies in West syndrome[J].Epilepsia Open,2018,3(2):134-166.
[28] Kim MY,Kim JH,Cho MH,et al.Urological problems in patients with Menkes disease[J].J Korean Med Sci,2019,34(1).doi:10.3346/jkms.2019.34.e4.
[29] Lenartowicz M,Krzeptowski W,Lipiński P,et al.Mottled mice and non-mammalian models of menkes disease[J].Front Mol Neurosci,2015,8.doi 10.3389/fnmol.2015.00072.
[30] Donsante A,Yi L,Zerfas PM,et al.ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model[J].Mol Ther,2011,19(12):2114-2123.
[31] Haddad MR,Choi EY,Zerfas PM,et al.Cerebrospinal fluid-directed rAAV9-rsATP7A plus subcutaneous copper histidinate advance survival and outcomes in a Menkes disease mouse model[J].Mol Ther Methods Clin Dev,2018,10:165-178.